Cargando…
Interstitial Pneumonitis after Treatment with Pemetrexed for Non-small Cell Lung Cancer
Pemetrexed is approved as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) with cisplatin and as a single agent for second-line treatment or for patients who show no disease progression after four cycles of platinum-based doublet induction chemotherapy as maintenan...
Autores principales: | Kim, Kyeong-Hyun, Song, Seo-Young, Lim, Kyu-Hyoung, Han, Seon-Sook, Kim, Se-Hyun, Cho, Jun Hwi, Park, Chan Woo, Lee, Seoungkoo, Lee, Hui-Young |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629367/ https://www.ncbi.nlm.nih.gov/pubmed/23613674 http://dx.doi.org/10.4143/crt.2013.45.1.74 |
Ejemplares similares
-
Pemetrexed-Induced Interstitial Pneumonitis: A Case Study and Literature Review
por: Waters, Michael J., et al.
Publicado: (2014) -
Pemetrexed induced pneumonitis
por: Dhakal, Binod, et al.
Publicado: (2011) -
A Case of Statin-Induced Interstitial Pneumonitis due to Rosuvastatin
por: Kim, Se Yong, et al.
Publicado: (2015) -
Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung
por: Jung, Minkyu, et al.
Publicado: (2013) -
Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer
por: Jo, Jaemin, et al.
Publicado: (2018)